Editorial Board
Editor-In-Chief
J. P. Donnelly (Nijmegen, The Netherlands)
Current Positions and Research Interests
Dr Donnelly retired in 2016 from his role as Coordinator of Supportive Care in the Department of Haematology of the Radboud University Nijmegen Medical Centre. He maintains an active interest in the management and diagnosis of infectious complications in haematological malignancies and stem cell transplantation in general, and in the diagnosis and management of invasive fungal diseases in particular. He has extensive knowledge of, and experience in, the design, conduct, analysis and reporting of clinical trials. He has been actively involved in the Journal of Antimicrobial Chemotherapy for several years, and was appointed its Editor-in-Chief in 2015.
Declaration of Interests
In the last 5 years, Dr Donnelly has received honoraria for lectures and consultancies from Astellas, F2G, Gilead, Pfizer and Shionogi. He is a director of the European Aspergillus PCR Initiative foundation (Dutch Chamber of Commerce number 09165918), which continues to support the Working Group Fungal PCR Initiative of the International Society of Human and Animal Mycology (ISHAM).
Senior Editors
J. C. Hurley (Melbourne, Australia)
Current Positions and Research Interests
James Hurley is a general and infectious disease physician at Grampians Health (Ballarat Health Services) and Associate Professor in Medicine at the Melbourne Medical School, University of Melbourne, Australia. His main research interests are the role of acquired infection and endotoxin in the mediation of sepsis, applications of meta-analysis techniques, hospital infection control and the epidemiology of nosocomial infections.
Declaration of Interests
None to declare.
A. P. Johnson (Compton, UK)
https://orcid.org/0000-0001-9358-230X
Current Positions and Research Interests
Prof. Alan Johnson is now retired but previously worked for Public Health England (now the UK Health Security Agency) undertaking surveillance of antibiotic resistance and antibiotic prescribing. He also taught on a number of academic courses on various aspects of medical microbiology.
Declaration of Interests
Prior to retirement Prof. Johnson was a member of the UK Government’s Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare-Associated Infections (APRHAI). He was also affiliated with the National Institute for Health Research (NIHR) Health Protection Research Units for Healthcare-associated Infections and Antimicrobial Resistance at Imperial College, London and the University of Oxford. He is currently a member of the Advisory Board of the Imperial College Health Protection Research Unit. Although retired he acts as the linkage lead involved in editing the annual reports of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) published by the UK Health Security Agency.
R. E. Lewis (Padua and Treviso, Italy)
https://orcid.org/0000-0002-2002-4339
Current Positions and Research Interests
Russell Lewis is an Associate Professor of Medicine-Infectious Diseases in the Department of Molecular Medicine at the University of Padua. His research focuses on strategies to improve the management of multidrug-resistant bacterial infections and invasive fungal diseases in immunocompromised patients. He specialises in the pharmacokinetic/pharmacodynamic analysis of antimicrobial therapy.
Declarations of Interests
Prof. Lewis has received honoraria for lectures from Gilead, Pfizer, Avir and F2G; and has received research funding from Gilead and Merck.
J. -Y. Madec (Lyon, France)
https://orcid.org/0000-0002-1893-8641
Current Positions and Research Interests
Dr Jean-Yves Madec is Research Director at the French Agency for Food, Environmental and Health Safety (ANSES) in Lyon, France. He is the head of a research group entitled ‘Antimicrobial Resistance and Virulence in Bacteria’ involved in the surveillance of antimicrobial resistance in animals in France. His research interests focus on molecular genetics and epidemiology of resistance in Gram-negative and Gram-positive bacteria of animal origin and issues regarding the animal–human transfer of antimicrobial resistance.
Declaration of Interests
None to declare.
L. Maes (Antwerp, Belgium)
http://orcid.org/0000-0002-2324-9509
Current Positions and Research Interests
Louis Maes is a veterinarian, and founder and director of the Laboratory for Microbiology, Parasitology and Hygiene (http://www.ua.ac.be/lmph) at the University of Antwerp. Until 2002, he was at the Johnson & Johnson divisions of Janssen Pharmaceutica (Beerse, Belgium) and Tibotec (Mechelen Belgium) involved in preclinical veterinary drug R&D. His academic research interests are antiprotozoal drug discovery with particular focus on leishmaniasis. Emeritus since September 2020 but currently still maintaining a part-time (10%) position with continued involvement in teaching, PhD research programmes and industrial collaborations.
Declaration of Interests
Louis Maes received funding for drug screening and evaluation from the World Health Organisation (WHO-TDR) and the Drugs for Neglected Diseases Initiatives (DNDi), and had ad hoc collaborations with several pharmaceutical industry partners on a fee-for-service basis. He is currently member of the Scientific Committee of the Belgian Federal Agency for Food Safety (FAVV).
R. L. Murphy (Chicago, USA)
https://orcid.org/0000-0003-3936-2052
Current Positions and Research Interests
Dr Rob Murphy is Professor of Medicine and Biomedical Engineering and the John P. Phair Professor of Infectious Diseases at Northwestern University where he is Executive Director, Havey Institute for Global Health. He holds an academic appointment as Visiting Professor of Immunology and Infectious Diseases at the Harvard T. H. Chan School of Public Health.
Dr Murphy’s primary research interest is in viral infections including the development of new antiretroviral drugs, direct acting antiviral agents for hepatitis B and C, and new antiviral agents for emerging infectious diseases including SARS-CoV-2. He has led multiple research and research training programs in sub-Saharan Africa focusing on HIV and its major comorbidities including tuberculosis, cancers, and point-of-care diagnostic/monitoring devices.
Dr Murphy was a longstanding investigator of the National Institutes for Allergy and Infectious Diseases (NIAID) Adult AIDS Clinical Trials Group (ACTG). Within the ACTG, he held multiple leadership positions including membership on the governing Executive Committee, Data Management Committee and Hepatitis Study Group.
Declaration of Interests
Dr Murphy is a scientific advisor for Biotron Limited, Biothea Pharma, ATEA Pharmaceuticals and Inspirotec Inc; he is a shareholder of ATEA Pharmaceuticals and Biothea Pharma.
L. Ostrosky-Zeichner (Houston, USA)
https://orcid.org/orcid.org/0000-0002-4784-7589
Current Positions and Research Interests
Dr Ostrosky-Zeichner is a professor of medicine and epidemiology, Memorial Hermann Endowed Chair, the Vice-Chair of Medicine for Healthcare Quality, the director of the Laboratory of Mycology Research, and the Division Chief at the Division of Infectious Diseases of the McGovern Medical School (a part of UTHealth). He also serves as the Chief Epidemiology Officer and Associate Director for Antimicrobial Stewardship for Memorial Hermann Healthcare System and UT Physicians.
Dr Ostrosky-Zeichner is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America and the Academy of the European Confederation of Medical Mycology. He is the President of the Mycoses Study Group and Educational Consortium and the Vice-President of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and has been a consultant to the US FDA and CDC. He has advanced training and experience in medical mycology, healthcare epidemiology, emerging infections, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality, and has published over 200 peer-reviewed articles on those topics.
Declaration of Interests
From 2021 to 2023, Dr Ostrosky-Zeichner has received grant support from and/or speaks/consults for Pfizer, Gilead, Merck , GSK, Astellas, Teva, Cidara, F2G, Scynexis, T2 Biosystems, Viracor Eurofins, Octapharma, Enanta, Melinta, Appilli, Iterum, GigaGen, US CDC and the US National Insitutes of Health.
S. Pournaras (Athens, Greece)
https://orcid.org/0000-0002-6298-9577
Current Positions and Research Interests
Spyros Pournaras is medical microbiologist. He is currently Professor at the Medical School of National and Kapodistrian University of Athens, Head of the Laboratory of Clinical Microbiology and the Infection Control Committee at the ATTIKON University Hospital, Athens, Greece. His research interests are antibiotic resistance mechanisms, resistance surveillance, molecular epidemiology of multidrug-resistant pathogens, antimicrobial stewardship and infection control. He is editorial board member of other journals in the fields of clinical microbiology and antimicrobial chemotherapy and also reviews regularly for many journals on antimicrobial chemotherapy, clinical microbiology and infectious diseases.
Declaration of Interests
He has occasionally received research funding from academia, pharmaceutical and diagnostics companies.
S. Schwarz (Berlin, Germany)
http://orcid.org/0000-0002-6303-8212
Current Positions and Research Interests
Prof. Dr med. vet. Stefan Schwarz is the managing director of the Institute of Microbiology and Epizootics in the School of Veterinary Medicine at the Freie Universität Berlin, Berlin, Germany. He is a specialist veterinarian in Microbiology, Epidemiology as well as Molecular Genetics and Gene Technology. His research group is involved in both surveillance of antimicrobial resistance and analysis of the molecular genetics of antimicrobial resistance. He teaches various academic courses at the Freie Universität Berlin. Prof. Schwarz is an evaluator of grant applications for several research organizations and also serves as editor or editorial board member of other journals.
Declaration of Interests
Prof. Schwarz is a member of the Veterinary Antimicrobial Susceptibility Testing (VAST) subcommittee of the Clinical and Laboratory Standards Institute (CLSI) and the chairman of the working group ‘Antimicrobial Resistance’ of the German Veterinary Medical Society. Since 2014, he is also a visiting professor at the China Agricultural University in Beijing, China.
M. Slavin (Melbourne, Australia)
https://orcid.org/0000-0002-8443-314X
Current Positions and Research Interests
Monica Slavin is Chair of Infections in Cancer and Transplantation at the University of Melbourne, Melbourne, Australia. She is Director of the Department of Infectious Diseases at the Peter MacCallum Cancer Centre, Melbourne, Australia and of the National Centre for Infections in Cancer funded by the National Health and Medical Research Council. She leads the Immunocompromised Host Infection Service at Royal Melbourne Hospital. She is treasurer of the International Immunocompromised Host Society, scientific officer for the European Society for Clinical Microbiology and Infectious Diseases Immunocompromised Host Working Group, council member of the TID section of the Transplantation Society and board member of the Mycoses Study Group Education and Research Consortium.
Her research focuses on diagnosing, preventing and treating opportunistic infections including invasive fungal infections in haematology and transplant patients.
Declaration of Interests
Dr Slavin has received funding or honoraria for lectures, conference attendance or consultancy from both academia and a number of pharmaceutical companies, including Roche, Gilead, Merck, Pfizer, F2G and Takeda.
E. Tacconelli (Verona, Italy)
Current Positions and Research Interests
Prof. Tacconelli is a Full Professor of Infectious Diseases and Head of the Division of Infectious Diseases at the University of Verona, Italy; Senior Consultant for research on antimicrobial resistance at the Department of Internal Medicine, University of Tuebingen, Germany; Chair of the European Committee on Infection Control (EUCIC) of ESCMID; and Chief Scientific Officer of the European Clinical Research Allaince on Infectious Diseases (ECRAID). In addition to being an Editor for the Journal of Antimicrobial Chemotherapy, she also serves on boards and committees of major stakeholders and other infectious disease journals. Her specific research interests include clinical aspects and treatment of healthcare-associated infections due to antimicrobial-resistant bacteria and public health.
Declaration of Interests
Prof. Tacconelli receives no industry funding or honoraria. Her current grant support is through the Horizon2020, IMI, WHO, GARDP, European Society of Infectious Diseases, Italian Agency of Medicine (AIFA), Fondazione CariVerona and Fondazione Verona.
A. Tsakris (Athens, Greece)
http://orcid.org/0000-0003-0656-4715
Current Positions and Research Interests
Athanasios Tsakris graduated as an MD from the Medical School of University of Athens, Greece and completed his training in Medical Microbiology at North Middlesex Hospital and the Central Public Health Laboratory, London. He received his PhD degree from the London School of Hygiene and Tropical Medicine, University of London. He is a Fellow in Medical Microbiology and Virology at the Royal College of Pathologists, London.
Prof. Tsakris is currently Professor and Head of the Department of Microbiology at the Medical School, University of Athens, Greece. He teaches various undergraduate and postgraduate academic courses at the University of Athens. His research interests include surveillance of multidrug-resistant pathogens, infection control activities and molecular mechanisms of antimicrobial resistance. He is an evaluator of grant applications for several organizations worldwide. Prof. Tsakris also serves as editor or on the editorial boards of other microbiology/infectious disease journals.
Declaration of Interests
Prof. Tsakris has occasionally received research funding from both academia and pharmaceutical companies.
Editorial Board
C. J. Achenbach (Chicago, USA)
Current Positions and Research Interests
Dr Achenbach is an Associate Professor of Medicine, Preventive Medicine and Biomedical Engineering at Northwestern University. His research is focused on ways to improve diagnosis, treatment and outcomes of patients with HIV and SARS-CoV-2 in the USA and low- and middle-income countries (LMICs). In particular, he is interested in the development of point-of-care and home-based diagnostics and the epidemiology of HIV, SARS-CoV-2 and other emerging infectious diseases.
Declaration of Interests
None to declare.
M. Aires-de-Sousa (Lisbon, Portugal)
https://orcid.org/0000-0001-5036-2446
Current Positions and Research Interests
Dr Aires-de-Sousa is a Professor of Microbiology and the chairman of the Direction Board at the Portuguese Red Cross Health School, Lisbon, Portugal. She is also a Researcher at the Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa. Her research interests include the molecular epidemiology and antimicrobial resistance mechanisms in Staphylococcus aureus and Enterobacteriaceae, as well as susceptibility testing of antiseptics.
Declaration of Interests
She has occasionally received research funding or honoraria from pharmaceutical companies.
R. Anthony (Bilthoven, The Netherlands)
https://orcid.org/0000-0002-0550-5273
Current Positions and Research Interests
Dr Richard Anthony leads the tuberculosis reference laboratory and research activities at the RIVM, Bilthoven, The Netherlands. His current research interests include the routine use of whole genome sequencing for genotying and the rapid detection of infection and drug resistance/prediction of susceptibility in Mycobacterium tuberculosis.
Declaration of Interests
Research in our laboratory is funded by national and European programmes.
J. Bacon (Salisbury, UK)
Current Positions and Research Interests
Dr Bacon has 23 years of experience working in the TB research field at Porton Down and is a PI for a team that has built its reputation on collaborative research. Her research focuses on gaining a deeper understanding of the effects of growing Mycobacterium tuberculosis under host-like conditions in a variety of laboratory models (which include controlled and defined conditions in chemostats, biofilms, and non-replicating persistence) on bacterial physiology/biochemistry, gene expression, pathogenicity, drug susceptibility and host–pathogen interactions. Her team develops unique and rare technologies and methods for the evaluation of candidate drugs against M. tuberculosis, non-tuberculosis mycobacteria and other infectious agents, such as SARS-CoV-2 and AMR bacteria.
Declaration of Interests
Dr Bacon receives funding for lectures, conference attendance, and research through Public Sector bodies, EU, UKRI and commercial routes. She is a Senior Honorary lecturer for University College London (UCL) and a Member of the UCL-TB group. She is also a Visiting Lecturer for the University of Bath and University of Reading. Dr Bacon contributes to the TB Research community through membership of the Acid-Fast Club, the STOP TB Partnership, London TB Workforce, and contributes to AMR research through membership of the Network for antimicrobial resistance and Infection Prevention (NAMRIP), UK Non-tuberculosis Mycobacteria (NTM) Network and the UKHSA AMR forum.
G. Biagini (Liverpool, UK)
Current Positions and Research Interests
Dr Giancarlo Biagini, B.Sc. Ph.D. is a Reader at the Liverpool School of Tropical Medicine, UK. Over the past 10 years at the school, Dr Biagini’s research interests have been in Drug Discovery, Pharmacology, Biochemistry and Physiology of human pathogens, principally Plasmodium falciparum and more recently Mycobacterium tuberculosis .
Declaration of Interests
Dr Biagini holds and has received grant funding from the EU, UK research councils and national and international charitable trusts but has not received any funding from commercial sources.
A. Brenciani (Ancona, Italy)
https://orcid.org/0000-0001-5191-3908
Current Positions and Research Interests
Andrea Brenciani is currently Professor of Microbiology and Clinical Microbiology in the Department of Biomedical Sciences and Public Health (Unit of Microbiology), at the Polytechnic University of Marche Medical School, Ancona, Italy. His main research interests focus on the analysis of antibiotic resistance mechanisms (especially oxazolidinones, glycopeptides and macrolides) and the characterization of mobile genetic elements (plasmids, transposons, integrative and conjugative elements and phages) by whole genome sequencing of Gram-positive bacteria of clinical, animal and environmental origin.
Declaration of Interests
None to declare.
R.J.M. Brüggemann (Nijmegen, The Netherlands)
http://orcid.org/0000-0002-7618-725X
Current Positions and Research Interests
Dr Brüggemann is Associate Professor in clinical pharmacology of anti-infectives at the Radboud university medical center in Nijmegen, The Netherlands.
He is responsible for the translational pharmacological research on antifungal drugs. His work involves three domains ranging from in vitro and animal research to trials in humans with strong national and international collaborations. Dr Brüggemann’s research involves the resolution of PK and PD behaviour and factors that impact this.
Declaration of Interests
Dr Brüggemann has served as a consultant to Astellas Pharma Inc., F2G, Amplyx (now Pfizer), Gilead Sciences, Munidpharma, Scynexis, Merck Sharp & Dohme Corp. and Pfizer Inc., and has received unrestricted and research grants from Gilead Sciences, F2G and Pfizer Inc. All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
G. Caljon (Antwerp, Belgium)
http://orcid.org/0000-0002-4870-3202
Current Positions and Research Interests
Guy Caljon is a full professor at the University of Antwerp in the Laboratory for Microbiology, Parasitology and Hygiene. He is a biologist with multidisciplinary expertise in immunology and drug discovery in the area of protozoan parasitic diseases (African trypanosomiasis and leishmaniasis) transmitted by insect vectors (tsetse flies and sand flies). His main research interest is in innate immune responses to vector-transmitted parasitic diseases and small molecule and biological antiparasitic drug pharmacodynamics and mechanism of action.
Declaration of Interests
Guy Caljon is supported for drug screening by the Drugs for Neglected Diseases Initiative (DNDi) and other industry partners on a fee-for-service basis. His research is funded by the Flemish and Belgian governments and European research programmes. He is a member and former chairman of the Belgian Society of Parasitology and Protistology and is also work group leader in COST Action network OneHealthDrugs.
A. Carattoli (Rome, Italy)
http://orcid.org/0000-0002-6120-6526
Current Positions and Research Interests
Dr Alessandra Carattoli is a Full Professor of Microbiology at the University of Rome La Sapienza, in the Faculty of Pharmacy and Medicine, Dept of Molecular Medicine. She is expert of plasmid identification and typing, and her research interests include horizontal transmission of antimicrobial resistance in Gram-negatives, bacterial genomics and metagenomics, molecular epidemiology of Escherichia coli, Klebsiella pneumoniae, Salmonella enterica and Acinetobacter baumannii.
Declaration of Interests
Dr Carattoli has received honoraria for lectures from Academia but not from commercial sources and research support from the Italian Ministry of Health and National Council of Research.
V. Cattoir (Rennes, France)
https://orcid.org/0000-0003-4026-9912
Current Positions and Research InterestsCurrent Positions and Research Interests
Prof. Vincent Cattoir is Professor of Clinical Microbiology at the University of Rennes as well as Head of the Bacteriology department of the University Hospital of Rennes, France, and Director of the ‘Enterococci’ lab affiliated with the National Reference Center for Antimicrobial Resistance. He is also the head of the INSERM U1230 research unit, where his current research focuses on identifying opportunistic traits involved in pathogenicity and antimicrobial resistance in opportunistic bacterial species such as Enterococcus faecium and Enterobacter cloacae complex. More recently, he has been coordinating or participating in several multicollaborative projects in France or Europe that aim to characterize novel antibacterial agents.
Declaration of Interests
Since 2013, Prof. Cattoir has received funding or honoraria for lectures, conference attendance or consultancy from both academia and a number of pharmaceutical companies including Accelerate Diagnostics, Astellas Pharma, AstraZeneca, Bio-Rad, bioMérieux, Correvio, Curetis, Eumédica, Menarini, Mérial, MSD, Mylan/Viatris, Pfizer and Sanofi. He is a member and the coordinator of the Antibiogram Committee of the French Society for Microbiology (CA-SFM).
P. Chandrasekar (Detroit, USA)
Current Positions and Research Interests
Dr Chandrasekar is a Professor of Medicine and Infectious Diseases in the Department of Internal Medicine at Wayne State University, Detroit, Michigan. He serves as the Chief of the Division of Infectious Diseases, and also Section Chief of Infectious Diseases at the Karmanos Cancer Center. His main interests are the diagnosis and management of infections in cancer patients and particularly those undergoing stem cell transplantation. He has been involved in the conduct and analysis of clinical studies involving immunocompromised patients for several years. He serves as a Chief Editor of MedScape.
Declaration of Interests
Dr Chandrasekar has received grant support/honoraria/consultancy fees for conduct of clinical trials/lectures/participation in Data Safety Monitoring boards. Associated companies include Merck, Pfizer, Astellas, Vical, Leonard-Meron Biosciences and Chimerix.
D. E. Corzo-Leon (Exeter, UK)
https://orcid.org/0000-0003-4012-1045
Current Positions and Research Interests
Dr Corzo-Leon is an infectious diseases specialist trained in Mexico with a PhD in Molecular Medical Mycology from the University of Aberdeen. Currently, she is a postdoctoral research fellow at the Medical Research Council Centre for Medical Mycology at the University of Exeter. Dr Corzo-Leon’s research interests are the study of (i) host–pathogen–pathogen interactions during fungal infections including fungal–viral and fungal–bacterial infections; (ii) immune and antimicrobial effects of genetic variation in human antimicrobial peptides; (iii) epidemiology and antimicrobial resistance in fungal infections; and (iv) Improving diagnostic capacities in LMICs.
Declaration of Interests
None to declare.
V. I. Enne (London, UK)
https://orcid.org/0000-0002-0250-6377
Current Positions and Research Interests
Dr Enne works at the Centre for Clinical Microbiology, University College London. She obtained her PhD investigating the persistence of antibiotic resistance from Barts and The London in 2001 and then completed antimicrobial resistance (AMR)-related post-doctoral work at the University of Bristol and QMUL, before moving to UCL in 2013. Her research focuses the development and evaluation of novel rapid molecular diagnostic strategies for bacterial infections and AMR and their implementation within healthcare systems to improve antimicrobial stewardship and patient outcomes. Other areas of research interest include mobile genetic elements, fitness cost of AMR, gene regulation and persistence of AMR in the absence of selection.
Declaration of Interests
Dr Enne has received research support, consultancy fees and in-kind contributions from several diagnostic companies including Curetis GmbH, BioMérieux and Oxford Nanopore.
H. J. Field (Cambridge, UK)
Current Positions and Research Interests
Dr Field has retired from his research and teaching post as Reader in Comparative Virology; formerly based at the Veterinary School, University of Cambridge. He was also Director of studies in Medical and Veterinary Sciences at Queens’ College, Cambridge where he remains a Life Fellow. His research focused on herpes viruses and antiviral agents, especially nucleoside analogues and helicase-primase inhibitors. His publications include original papers and reviews on the development of antivirals in laboratory infection models and the mechanisms of antiviral resistance.
Declaration of Interests
Dr Field serves on the Editorial Boards of Antiviral Chemistry and Chemotherapy and Future Virology. He currently has no other conflicting interests.
H. Fifer (London, UK)
https://orcid.org/0000-0001-7756-403X
Current Positions and Research Interests
Dr Helen Fifer is a Consultant Medical Microbiologist working in the Blood Safety, Hepatitis, STI & HIV Division of the UK Health Security Agency. She is the lead microbiologist for bacterial sexually transmitted infections (STIs) and her main interest is antimicrobial resistance in STIs. She is a member of the British Association of Sexual Health and HIV Clinical Effectiveness Group and is the lead author of the UK Gonorrhoea treatment guideline. She is also an advisor to the NHS Infectious Diseases in Pregnancy Screening Programme.
Declaration of Interests
None to declare.
Tommaso Giani (Florence, Italy)
https://orcid.org/0000-0001-7293-058X
Current Positions and Research Interests
Tommaso Giani is an Associate Professor of clinical microbiology at the University of Florence, Italy. He has long-standing experience in diagnosis and surveillance of antimicrobial resistant bacterial infections. His research interest focuses on phenotypic and genotypic characterization of acquired resistance mechanisms in bacterial pathogens and characterization of the molecular basis of the emerging resistances to last resort molecules.
R. M. Hall (Sydney, Australia)
https://orcid.org/0000-0003-2062-3312
Current Positions and Research Interests
Prof. Ruth Hall is in the School of Life and Environmental Sciences at the University of Sydney, Sydney, Australia. Work in her laboratory focuses on the molecular genetics and genomics of antibiotic resistance in Gram-negative bacteria (Escherichia coli, Salmonella enterica, Klebsiella pneumoniae, Acinetobacter baumannii) with particular interests in the identification, characterization and evolution of regions carrying resistance genes, and the molecular mechanisms that lead to the dissemination of the resistance genes.
Declaration of Interests
Prof. Hall’s research has been supported by government funding from the National Health and Medical Research Council (NHMRC). She has not received any funding from commercial sources.
C. A. Hawkins (Chicago, IL, USA)
https://orcid.org/0000-0001-7228-6317
Current Positions and Research Interests
Dr Hawkins is Professor of Medicine and Infectious Diseases and Director, Center for Global Communicable and Emerging Infectious Diseases, Robert J. Havey, MD Institute for Global Health, at Northwestern University’s Feinberg School of Medicine, Chicago. Dr. Hawkins’ research focuses on the epidemiology of HIV and HIV/viral hepatitis coinfections; point-of-care diagnostics for HBV and HCV; biomarkers for the diagnosis, monitoring and prognostication of persons with HBV; and clinical trials of novel and curative hepatitis therapeutics. She leads multiple research and research training programmes in sub-Saharan Africa focusing on HIV and related comorbidities.
Declaration of Interests
None to declare.
A. Hill (Liverpool, UK)
Current Positions and Research Interests
Dr Andrew Hill is a Senior Visiting Research Fellow at Liverpool University. Dr Hill has a first degree from Oxford University and a PhD from the University of Amsterdam. His speciality is the design and analysis of HIV clinical trials. He is working on antiretroviral treatment for developing countries.
Declaration of Interests
Dr Andrew Hill is a Senior Visiting Research Fellow at Liverpool University. Dr Hill has a first degree from Oxford University and a PhD from the University of Amsterdam. His speciality is the design and analysis of HIV clinical trials. He is working on antiretroviral treatment for developing countries.
R. Hope (London, UK)
https://orcid.org/0000-0003-2838-6833
Current Positions and Research Interests
Dr Hope works for the UK Health Security Agency (UKHSA) (formally Public Health England) in London undertaking surveillance of antibiotic resistance and healthcare associated infections. He currently heads the section responsible for Gram-negative organisms with in the HCAI, Fungal, AMR, AMU & Sepsis Division. Prior to this Russell ran surveillance programmes for the UKHSA’s Antibiotic Resistance Monitoring and Reference Laboratory. Interests are focused on the epidemiology of infections cause by antimicrobial resistant pathogens, automated surveillance data, artificial intelligence for improved clinical diagnostics and antibiotic resistance mechanisms within the Enterobacteriaceae.
Declaration of Interests
Dr Hope has received support for research projects and/or conference attendance from a number of companies including, Pfizer, Johnson & Johnson, Novartis, and Smith and Nephew.
A. D. Irwin (Brisbane, Australia)
https://orcid.org/0000-0001-8974-6789
Current Positions and Research Interests
Dr Adam Irwin is a Principal Research Fellow in Paediatric Infectious Diseases at the University of Queensland and Queensland Children’s Hospital in Brisbane, Australia. His research focuses on the early recognition of invasive infections and sepsis, and the optimal use of antimicrobials in children. He is the medical co-chair of the Queensland Paediatric Sepsis Program and a member of the Australian Group on Antimicrobial Resistance-Kids Steering Committee. He is a recipient of a National Health and Medical Research Council Emerging Leadership Fellowship to investigate the management of MDR Gram-negative infections in children.
Declaration of Interests
Dr Irwin has received honoraria for lectures from Gilead and bioMérieux, paid to his institution, the University of Queensland, and has received research funding from Gilead.
P. Kanki (Boston, USA)
https://orcid.org/orcid.org/0000-0003-4739-4572
Current Positions and Research Interests
Phyllis Kanki, DVM, DSc is a Professor of Immunology and Infectious Disease, Department of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health. For several decades she led research programs in Senegal focusing on the identification and attenuated biology of HIV-2, cross protection between HIV-2 and HIV-1 and differential disease development by HIV genotypes. Research interests include the virology, molecular epidemiology of HIV in Africa along with implementation science work to improve HIV outcomes. In addition, recent research has sought to characterize antibody and T cell immunity to emerging or re-emerging viral fever pathogens such as Ebola virus, Zika, dengue and SARS CoV-2 virus in West Africa.
Declaration of Interests
Prof. Kanki has received funding or honoraria for lectures, conference attendance or consultancy from both academia and the US Government but not the pharmaceutical industry. She is a member of the scientific advisory board for African Centre of Excellence for Genomic Infectious Diseases.
R. J. Koerner (Strasbourg, France)
Current Positions and Research Interests
Dr Koerner is medical microbiologist. He worked as a consultant microbiologist and infection control doctor for 28 years for the National Health Service (NHS) of the UK. He was holding a honorary contract as Clinical Senior Lecturer of Newcastle University. He recently left the NHS and is now a director of Northumbria Engineering and Technology. Under the auspices of this company he continues to work as an independent consultant microbiologist.
His specific clinical interests are diagnosis and management of infection in the critical care setting, optimizing antimicrobial chemotherapy by applying PK/PD parameters, healthcare associated diseases, and antimicrobial prescribing/stewardship.
Declaration of Interests
In the past some of his students received unconditional educational grants from Pfizer, Bayer and Novartis.
D. C. M. Kong (Melbourne, Australia)
https://orcid.org/0000-0002-5022-9060
Current Positions and Research Interests
David C. M. Kong is an Associate Professor in the School of Medicine at Deakin University and the Deputy Director of Pharmacy at Grampians Health. He also has an adjunct appointment at the Monash Institute of Pharmaceutical Sciences, Monash University. His research interests include antimicrobial stewardship, prevention and management of opportunistic infections including invasive fungal infections in transplant and haematology patients, PK/PD of antimicrobials and health economics.
Declaration of Interests
David has received funding for conference attendance, consultancy and research support from both academia and a number of pharmaceutical companies, including Merck, Pfizer and F2G.
J. Lipman (Brisbane, Australia)
https://orcid.org/0000-0002-5965-9876
Current Positions and Research Interests
Current Positions and Research Interests
Prof Lipman is Chair of Trauma-related Clinical Research, Jamieson Trauma Institute, Royal Brisbane and Women’s Hospital. He is also Emeritus Professor at The University of Queensland.
His research interests encompass sepsis in general and antibiotic pharmacokinetics in particular.
Declaration of Interests
None to declare.
T. P. Lodise (Albany, USA)
https://orcid.org/0000-0002-4730-0655
Current Positions and Research Interests
Thomas Lodise, PharmD, PhD, is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York. He is also an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. Integrating his dual interests in research and patient care, his overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. His research encompasses three interrelated domains: pharmacokinetics/pharmacodynamics (PK/PD), epidemiology and outcomes. He has published over 200 peer-reviewed articles in numerous medical journals. His publications include a number of seminal papers on MRSA, carbapenem-resistant Gram-negative infections, vancomycin PK/PD, β-lactam PK/PD, clinical applications of population pharmacokinetic modelling and Monte Carlo simulation, and precision antibiotic dosing.
Declaration of Interests
Dr Lodise has received honoraria or grant funding from the following companies: Basilea, Cidara, DoseMe, Edenbridge, Ferring, ICPD, GlaxoSmithKline, Genentech, Melinta, Merck, Paratek, Roche, Seres, Shionogi, Spero, Utility, Wockhardt and Venatrox. Dr Lodise is Pharmacokinetic Lead for the Antibiotic Resistance Leadership Group (ARLG) (https://arlg.org), an initiative funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
J.-Y. Maillard (Cardiff, UK)
https://orcid.org/Orcid: 0000-0002-8617-9288
Current Positions and Research Interests
Jean-Yves Maillard is a Professor of Pharmaceutical Microbiology at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University. His field of expertise concerns biocides; their activity against all pathogens and biofilms, mechanisms of action, emerging microbial resistance and cross-resistance to antimicrobials, biocide formulations and efficacy test protocols. He is also working as a consultant on matters related to biocides.
Declaration of Interests
Jean-Yves Maillard has received on occasion honoraria for giving lectures at conferences. His academic research is partly funded by the industry through Cardiff University. He is the Director of Biocide Consult Ltd, which provides consultancy on biocides and biocidal products to the industry. He sits on the steering committee of the Safer Disinfectant Network.
V. Mallet (Paris, France)
https://orcid.org/0000-0003-2219-9201
Current Positions and Research Interests
Vincent Mallet, MD, PhD is managing senior physician in the Department of Hepatology at Cochin Hospital and full professor at the University of Paris Cité, Paris, France.
Vincent Mallet has worked on basic and clinical aspects of liver diseases since 1999. His main interests are the burden of HBV, HCV and HEV infections in immunocompromised hosts, the immunopathogenesis of HCV, HBV and HEV infections, novel immunomodulatory therapies for cancer and hepatocellular carcinoma, and big data to describe the natural courses of diseases.
Declaration of Interests
Vincent Mallet is a speaker and consultant for AbbVie Inc.
E. Martinez (Barcelona, Spain)
https://orcid.org/0000-0002-6911-8846
Current Positions and Research Interests
Dr Martinez is a Senior Consultant, Infectious Diseases, Hospital Clínic. Associate Professor of Medicine, University of Barcelona. Former President of Spanish HIV Society (GeSIDA) and the current President of European AIDS Society (EACS). He is a member of the Scientific Committee of the International Workshop on Adverse Drug Reactions and Co-morbidities in HIV and co-chair of the International Symposium on Neuropsychiatry and HIV. He is also a member of the Assessor Council of Hospital Medicine (Catalan Health Service) and of the Steering Committee of NEAT-ID, REPRIEVE-EU and EuroSIDA. He is an Associate Editor of HIV Medicine and member of the Editorial Board of AIDS Research and Therapy, Clinical Infectious Diseases, The Journal of Infectious Diseases, Journal of Acquired Immune Deficiency Syndromes, and AIDS. His fields of interest include simplification of antiretroviral therapy, antiretroviral toxicity, comorbidities and chronic care for adults with HIV.
Declaration of Interests
Esteban Martinez has received honoraria, speaker fees, consultant fees and funds for research from Gilead, Janssen, Merck Sharp & Dohme and ViiV Healthcare.
J. Meletiadis (Athens, Greece)
https://orcid.org/https://orcid.org/0000-0002-8869-1509
Current Positions and Research Interests
Joseph Meletiadis is Associate Professor of Microbiology at the Medical School of National and Kapodistrian University of Athens, head of Mycology Unit at the Clinical Microbiology Laboratory of Attikon University General Hospital of Athens, Greece and visiting scientist in the Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands. He is the clinical data coordinator of the EUCAST subcommittee for antifungal susceptibility testing since 2014 and PK/PD expert of the EUCAST steering committee since 2019. Dr Meletiadis is a fellow of the European Society of Clinical Microbiology and Infectious Diseases (FESCMID) Academy and of the European Confederation of Medical Mycology (FECMM) Academy. His main research interests are antimicrobial pharmacokinetics and pharmacodynamics, fungal and bacterial infection models, molecular diagnostics and identification, antimicrobial susceptibility testing, in vitro and in vivo drug combinations.
Declaration of Interests
Dr Meletiadis has received research funding or honoraria for lectures, conference attendance or consultancy from academia and pharmaceutical companies.
C. F. Neoh (Melbourne, Australia)
Current Positions and Research Interests
Dr Neoh completed her PhD on optimizing the use of high-cost antifungal agents in immunocompromised hosts at Monash University, Australia and was awarded the Vice-Chancellor’s Commendation for Doctoral Thesis Excellence. She was then inducted as a Fellow of the European Confederation of Medical Mycology (ECMM) and involved in the development of the global clinical guideline for management and diagnosis of rare mould infections and candidiasis. Dr Neoh is a postdoctoral researcher at the National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia. Her research interest is in the fields of fungal infections and antifungal use, with the focus on pharmacoeconomics and outcome research, surveillance, stewardship and digital health.
Declaration of Interests
Dr Neoh has received research funding or honoraria for lectures, conference attendance or consultancy from academia and pharmaceutical companies.
A. J. O’Neill (Leeds, UK)
Current Positions and Research Interests
Alex O’Neill is Professor of Antimicrobial Research in the Faculty of Biological Sciences at the University of Leeds, UK. He heads a research group whose aim is to better understand and to address the problems presented by antibiotic resistance in bacterial pathogens; current major areas of focus include elucidating the molecular detail of antibiotic resistance mechanisms in Staphylococcus aureus, and the discovery and biological characterization of novel antibacterial drug candidates.
Declaration of Interests
Prof. O’Neill has received funding for research or consultancy from a variety of commercial sources including Blueberry Therapeutics, Cubist (now Merck), Oxford Drug Design and Smith & Nephew.
S. Partridge (Sydney, Australia)
https://orcid.org/0000-0002-0666-8330
Current Positions and Research Interests
Dr Sally Partridge is employed as a Senior Hospital Scientist by the Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, Australia, working in The Westmead Institute for Medical Research, The University of Sydney. She also holds an honorary position as Principal Research Fellow in the Sydney Medical School, The University of Sydney. Her research interests are the genetics (mobile genetic elements, resistance plasmids, bioinformatics) and genetic epidemiology of mobile antibiotic resistance in Gram-negative bacteria, particularly the Enterobacteriaceae.
Declaration of Interests
Dr Sally Partridge has received funding from the Australian National Health and Medical Research Council (NHMRC) as a Chief Investigator on Project grants, the Australian National Data Service (ANDS) and the Australian Society for Microbiology, but not from commercial sources.
L. Poirel (Fribourg, Switzerland)
https://orcid.org/0000-0001-5160-5286
Current Positions and Research Interests
Dr Laurent Poirel is an Associate Professor at the Medical and Molecular Microbiology Unit, Dept of Medicine, Faculty of Science of the University of Fribourg, Switzerland, and at the Swiss National Reference Center for Emerging Resistance to Antibiotics (NARA), Switzerland. His research interests include emerging mechanisms of resistance to β-lactams, polymyxins, aminoglycosides and quinolones in Gram-negative rods. He is specialized on the genetics of acquisition of broad-spectrum β-lactamases in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii, plasmid-mediated quinolone resistance, and polymyxin resistance determinants in Enterobacteriaceae. He has co-developed a large series of rapid diagnostic tests for antibiotic resistance, including the Carba NP test. He is the author of 600 publications in international journals and member of several journal editorial boards.
Declaration of Interests
He has occasionally received research funding or honoraria from pharmaceutical companies.
R. Rautemaa-Richardson (Manchester, UK)
https://orcid.org/0000-0002-1071-6040
Current Positions and Research Interests
Dr Riina Richardson is a Senior Clinical Lecturer in Infectious Diseases and Medical Education in the Division of Evolution, Infection and Genomics, University of Manchester and an Honorary Consultant Medical Mycologist at the Manchester University NHS Foundation Trust. Dr Richardson is the Clinical Head of Service for the Mycology Reference Centre Manchester and a member of the Infectious Diseases team. She is an internationally recognised expert, senior researcher, educator and clinician in the field of fungal infectious diseases. She is an academic clinician who has published over 180 peer-reviewed articles and books or book chapters in the field of medical microbiology, mucosal immunology, infectious diseases and oral medicine, and has an h-index of 51.
Dr Richardson has special expertise in the management of a spectrum of mycoses including fungal sinusitis and infections in compromised patients, and a special interest in chronic mucosal candidosis and mucosal immunology. She also has expertise in antimicrobial stewardship and infection prevention. She is an author of the recently updated BASHH guideline on vulvovaginal candidiasis as well as the ECMM/ISHAM candidiasis and rare yeasts guidelines. She is the lead for infectious diseases learning for Manchester Medical School, the Chair of the UK SMI Bacteriology Working Group, and an Educational Officer and lead for the ESCMID Academy.
Declaration of Interests
None to declare.
K.K. Scarsi (Omaha, USA)
https://orcid.org/0000-0001-9406-693X
Current Positions and Research Interests
Dr Kim Scarsi is a Professor in the College of Pharmacy and College of Medicine at the University of Nebraska Medical Center in Omaha, NE, USA. She received her Doctor of Pharmacy degree from Drake University, completed postgraduate residency training at Northwestern Memorial Hospital and received her Master of Science in Clinical Investigation from Northwestern University. Her research interests include the pharmacology of antiretroviral agents and medications commonly used to treat co-infections with HIV, such as tuberculosis, pharmacological considerations related to gender, and management of HIV-related drug interactions.
Declaration of Interests
Dr Scarsi has received research support paid to her institution from Organon LLC. She has not received honoraria from industry sources. Her current grant support is through the National Institutes of Health, both NIAID and NICHD, and UNITAID.
S. Simjee (Birmingham, UK)
Current Positions
Shabbir Simjee completed a PhD in 1998 from the University of Birmingham Medical School. After a brief time in research he went to work at the US FDA between 2000 and 2003 at the Centre for Veterinary Medicine. Shabbir is past chair of the VetPath programme, a pan-European AMR monitoring programme, and past co-chair of the CLSI veterinary antimicrobial susceptibility testing sub-committee. Shabbir is currently serving as chief Medical Officer at Elanco Animal Health with global responsibilities for Elanco’s antimicrobial portfolio.
Declaration of Interests
Employed by Elanco Animal Health and hold stocks in Elanco Animal Health.
B. Surial (Bern, Switzerland)
https://orcid.org/0000-0002-1402-974X
Current Positions and Research Interests
Dr Bernard Surial works as an infectious diseases physician in the Department of Infectious Diseases at the University Hospital of Bern (Inselspital) in Switzerland and is actively involved in the Swiss HIV Cohort Study. His research focuses on optimizing HIV antiretroviral treatment, which includes short- and long-term toxicity and treatment simplification (especially in treatment-experienced individuals). He has a strong methodological interest in observational data analysis (e.g. causal inference) and the conduction of randomized clinical trials.
Declaration of Interests
Dr Surial has received financial support to his institution for travel grants from Gilead Sciences and ViiV healthcare, and for advisory boards from Gilead Sciences.
E. L. Sweeney (Queensland, Australia)
https://orcid.org/0000-0002-3199-6432
Current Positions and Research Interests
Dr Sweeney is a postdoctoral researcher at the University of Queensland Centre for Clinical Research. She received her PhD in 2015, where she characterized the role and pathogenesis of Ureaplasma spp. in adverse pregnancy and birth outcomes. Dr Sweeney’s research focuses on the development of molecular diagnostic tools to diagnose infection and characterize antimicrobial resistance, with a view to guiding selection of antimicrobial treatments for clinically challenging infections, such as Mycoplasma genitalium. She helped to review the 2021 Australian STI management guidelines for M. genitalium and is also a member of the International Committee on Systematics of Prokaryotes Mollicutes subcommittee.
Declaration of Interests
Dr Sweeney works closely with industry partners, SpeeDx Pty Ltd, designing and evaluating molecular diagnostic tools to guide treatment for antimicrobial resistant M. genitalium infections. This work is supported by a REDI industry fellowship. Dr Sweeney has also received research project funding from the Children’s Hospital Foundation, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine research fund and Pathology Queensland’s Study, Education and Research Trust Fund.
W. van Schaik (Birmingham, UK)
https://orcid.org/0000-0001-5832-0988
Current Positions and Research Interests
Willem van Schaik is Professor of Microbiology and Infection at the Institute of Microbiology and Infection of the University of Birmingham. His research group combines experimental tools in molecular biology and biochemistry with the opportunities offered by the development of novel, high-throughput DNA sequencing technologies and bioinformatics to elucidate the mechanisms by which harmless commensals transition into successful multidrug-resistant opportunistic pathogens. In addition, he studies the role of complex microbial ecosystems, in particular the human gut microbiome, as reservoirs of antibiotic resistance genes.
Declaration of Interests
Prof. Van Schaik has received consultancy fees from Vedanta Biosciences Inc.
Y. Wang (Beijing, China)
https://orcid.org/0000-0002-5928-9377
Current Positions and Research Interests
Dr Yang Wang is a Professor in National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University in Beijing, China. He is also the director of Key Laboratory of Animal Antimicrobial Resistance Surveillance, Ministry of Agriculture and Rural Affairs, PR China. His current research interests focus on emerging antimicrobial resistance in bacteria of animal, human and environmental origin, with a particular interest in the prevalence, dissemination and control of resistance to critically important or last-resort antimicrobial agents, such as carbapenems, polymyxins, oxazolidinones and tigecycline.
Declaration of Interests
Dr Wang receives grant funding from the Ministry of Science and Technology of China and the National Natural Science Foundation of China.
G. Werner (Wernigerode, Germany)
https://orcid.org/0000-0002-2225-5122
Current Positions and Research Interests
Guido Werner works as a Medical Microbiologist in the Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Germany. He is Head of the Division ‘Nosocomial Pathogens and Antimicrobial Resistances’ and of the National Reference for Staphylococci and Enterococci. He is also Professor for Medical Microbiology and gives lectures on this subject at the Georg-August University Goettingen and the Technical University Brunswick. His main research interests are in methods of rapid and molecular diagnostics, molecular strain characterization/typing including NGS of bacterial pathogens and all biological and epidemiological aspects of antimicrobial resistance. He has worked for 18 months as a national expert at the European Commission, General Directorate ‘Health and Consumer Protection’ in the Unit ‘Health threats’ (DG SANCO C3) and is the nominated ‘National Microbiology Focal Point’ of a microbiological working group at the European CDC, Stockholm, Sweden. He is a long-standing and active member of several national and international medical societies and their working parties like the Paul Ehrlich Society for Infection Therapy, the German Society for Hygiene and Microbiology DGHM and ESCMID. He is also member of the German National Antimicrobial Susceptibility Testing Committee NAC.
Declaration of Interests
None to declare
Nathan Wiederhold (San Antonio, USA)
https://orcid.org/0000-0002-2225-5122
Current Positions and Research Interests
Nathan Wiederhold is Professor in the Departments of Pathology & Laboratory Medicine, and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio. He also serves as the director of the Fungus Testing Laboratory, a reference mycology laboratory that receives clinical specimens from institutions throughout the USA for fungal identification, antifungal susceptibility testing and therapeutic drug monitoring. His research focuses on the in vitro and in vivo evaluation of novel antimicrobials in preclinical development.
Declaration of Interests
Dr Wiederhold has received research support from Astellas, bioMerieux, F2G, Maxwell Biosciences, Mycovia, and Sfunga and has served on an advisory board for F2G.
M. A. Zeitlinger (Vienna, Austria)
https://orcid.org/0000-0002-1873-3953
Current Positions and Research Interests
Prof. Markus Zeitlinger is Head of the Department of Clinical Pharmacology, Medical University of Vienna, Austria. Beside clinical trial design his scientific interests cover antimicrobial agents with focus on early phases of clinical research and pharmacokinetics/pharmacodynamics (PK/PD). As scientific expert to the European Medicines Agency (EMA) he has strong interest in regulatory aspects of drug development.
Declaration of Interests
His department performs around 40 clinical studies per year, approximately half of them in collaboration with industry. He is also involved as consultant or DSMB board activities for some pharmaceutical companies. Lastly Prof. Zeitlinger is work-package leader of several European research consortia that focus on antimicrobial drug development.
Methodological Advisors
M. Cruciani (Verona, Italy)
Current Positions and Research Interests
Mario Cruciani, MD, is now retired but previously worked as an infectious diseases specialist in Verona, Italy. He is still active, and his main interest in the field of research is the methodology of systematic reviews and meta-analyses of interventions and of diagnostic test accuracy. He is a Cochrane reviewer and associate editor of the Cochrane Clinical Answers, and member of the Fungal PCR Initiative (FPCRI), a branch of the International Society for Human & Animal Mycology (ISHAM).
Declaration of Interests
None to declare.
T. Lamagni (London, UK)
https://orcid.org/0000-0002-3965-8323
Current Positions and Research Interests
Theresa Lamagni graduated in Psychology (BSc) in 1994 and came to work for the Public Health Laboratory Service (now UK Health Security Agency, UKHSA) Communicable Disease Surveillance Centre in 1995 as a research assistant within the HIV & STI Department. During this time she completed an MSc in Epidemiology at the London School of Hygiene & Tropical Medicine. In May 2001, she joined the newly formed Healthcare Associated Infection & Antimicrobial Resistance Department within the PHE in London as a senior epidemiologist. She completed her PhD on the epidemiology of severe group A streptococcal infections in Europe at the University of Helsinki in 2008. She is currently a Section Head within the UKHSA HCAI & AMR Division, leading on national surgical site and streptococcal infection surveillance. She is involved in a number of national and international projects concerned with developing evidence to inform public health policies.
Declaration of Interests
None to declare.
M. Paesmans (Brussels, Belgium)
Current Positions and Research Interests
Marianne Paesmans is currently Head of the Information Unit for Institut Bordet/Hôpital Universitaire de Bruxelles and working as biostatistician for clinical trials and other research projects, with a special focus on clinical research in oncology and in febrile neutropenia occurring in oncological patients. She has been involved in studies from MASCC, EORTC-IDG and in academic trials sponsored by Institut Jules Bordet. She also has an interest in ethics for research projects (she is presently chair of the hospital ethics committee).
Declaration of Interests
None to declare.
